EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Randomized phase II trial of BCDT (carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifens) with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma



Randomized phase II trial of BCDT (carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifens) with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma



British Journal of Cancer 77(8): 1280-1286



The purpose of this study was to evaluate in a randomized phase II trial the efficacy and toxicity of combination biochemotherapy compared with chemotherapy alone in patients with metastatic melanoma.

(PDF emailed within 1 workday: $29.90)

Accession: 009295890

Download citation: RISBibTeXText



Related references

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. British Journal of Cancer 77(8): 1280-1286, 1998

Randomized phase II trial of BCDT , cisplatin, dacarbazine and tamoxifens with or without interferon alpha. British Journal of Cancer 77(8): 1280-1286, April, 1998

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clinical Cancer Research 6(6): 2201-2208, 2000

A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Research 7(2): 147-151, 1997

Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clinical Oncology ) 13(6): 458-465, 2002

Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Research 5(4): 273-276, 1995

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. Journal of Clinical Oncology 20(6): 1600-1607, 2002

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). British Journal of Cancer 84(8): 1036-1042, 2001

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 16(5): 1743-1751, 1998

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 26(35): 5748-5754, 2008

Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a. Medizinische Klinik 91 Suppl 3(): 44-49, 1996

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology 23(27): 6747-6755, 2005

Clinical findings in patients with metastatic melanoma during treatment with dacarbazine dtic and interferon alpha rlfn alpha. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 299, 1990